ABSTRACT
The European Paediatric Pulmonary Vascular Disease (PVD) Network is a registered, non-profit organisation that strives to define and develop effective, innovative diagnostic methods and treatment options in all forms of paediatric pulmonary hypertensive vascular disease, including specific forms such as pulmonary arterial hypertension (PAH)-congenital heart disease, pulmonary hypertension (PH) associated with bronchopulmonary dysplasia, persistent PH of the newborn, and related cardiac dysfunction. Methods The writing group members conducted searches of the PubMed/MEDLINE bibliographic database and held five face-to-face meetings with votings. Clinical trials, guidelines, and reviews limited to paediatric data were searched using the terms 'pulmonary hypertensio n' and 5-10 other keywords, as outlined in the other nine articles of this special issue. Class of recommendation (COR) and level of evidence (LOE) were assigned based on European Society of Cardiology/American Heart Association definitions and on paediatric data only, or on adult studies that included >10% children. Results A total of 9 original consensus articles with graded recommendations (COR/LOE) were developed, and are summarised here. The topics included diagnosis/ monitoring, genetics/biomarker, cardiac catheterisation, echocardiography, cardiac magnetic resonance/chest CT, associated forms of PH, intensive care unit/ventricular assist device/lung transplantation, and treatment of paediatric PAH. Conclusions The multipaper expert consensus statement of the European Paediatric PVD Network provides a specific, comprehensive, detailed but practical framework for the optimal clinical care of children with PH.
Pulmonary hypertensive vascular disease (PHVD) is a fatal disease characterised by pulmonary vascular remodelling, leading to elevated pulmonary arterial pressure, right ventricular dysfunction, left ventricular compression and consequently heart failure. [1] [2] [3] [4] [5] [6] Despite significant advances in pulmonary arterial hypertension (PAH)-targeted therapies, survival of children and adults with idiopathic PAH and other forms of group 1 pulmonary hypertension (PH), such as persistent PAH after repair of congenital heart disease (CHD), remains poor. [7] [8] [9] [10] [11] [12] Morbidity and mortality of paediatric PH represent substantial and growing healthcare burden: [12] [13] [14] [15] From 1997 to 2012, shifts in case mix toward paediatric PH not associated with CHD, non-cardiac procedures and care in urban teaching hospitals have been noted in a recent retrospective study in the USA. 15 Based on a separate analysis of the period 2000-2009, the number of PH-related hospitalizations of children is increasing, and the overall mortality for PH-related hospitalizations is greater than that for hospitalizations not associated with PH (5.7% vs 0.4%; odds ratio: 16.22 (95% CI 14.8% to 17.8%), p<0.001). 16 Nevertheless, PH-associated mortality has been decreasing over the recent years in children 16 17 and adults 9 10 (box 1).
Objectives of the expert consensus statement of the European Paediatric Pulmonary Vascular Disease (PVD) Network
We were seeking to develop a framework that better defines the course of paediatric PH, identifies current gaps in our knowledge and provides a consensus statement with practical recommendation on how to best manage paediatric PH in diverse settings, acknowledging that most recommendations will have level of evidence (LOE) B or C. The 10 documents, including this executive summary, do not comprehensively review the pathobiology and clinical findings of paediatric PH, but rather contain practical recommendations for healthcare providers treating children and adolescents with different forms of PH.
The objectives of this multipaper consensus statement were (1) to discuss the most recent classifications of PH: World Symposium, Nice, 2013; progressive post-haemorrhagic ventricular dilatation (PPHVD) pulmonary vascular resistance index Panama 2011; European Society of Cardiology (ESC)/European Respiratory Society (ERS), 2015; (2) to summarise clinical study results and their limitations, (3) to provide graded, evidenceand expert-based recommendations for the diagnosis and treatment of infants, children and adolescents with PH (including CHD/Eisenmenger syndrome), according to the grading system provided by American Heart Association (AHA) and ESC, (4) to address features specific to PH forms in childhood, (5) to define the multiple gaps in our knowledge on paediatric PH, (6) make suggestions on future trial design and (7) to discuss emerging PH therapies (safety and efficacy).
METHODOLOGY The European Paediatric PVD Network
The European Paediatric PVD Network is a registered nonprofit organisation that is independent of any medical-scientific society and industry. The network strives to define and develop effective, innovative diagnostic methods and treatment options in all forms of paediatric PHVD, including specific forms such as PAH--CHD, PH associated with bronchopulmonary dysplasia (BPD), persistent PH of the newborn (PPHN) and related cardiac dysfunction. In order to achieve these objectives, an interdisciplinary writing group (WG) was assembled to develop a multipaper expert consensus statement that is being published in this special issue of Heart. 20 is currently undergoing revisions and modifications, as practicing PH doctors aim to apply the detailed paediatric-specific classification. Hence, this multipaper expert consensus statement on the paediatric PH by our network is timely indeed. 
Composition of the PVD

Recommendations
COR LOE
Children with suspected or confirmed PH/PPHVD should be referred to, comprehensively evaluated and treated in multidisciplinary, specialised paediatric centres.
I C
The initial evaluation should include a comprehensive medical history, thorough physical examination, assignment to a functional class and formal assessment of cardiac function (ECG and echocardiogram). This should be followed by further diagnostic testing to delineate the PH aetiology-ideally prior to the initiation of therapy. 24 and cardiac magnetic resonance/CT.
25
▸ Moreover, we addressed two disease-specific, complex and common patient groups separately: (1) PH/PHVD associated with CHD, including recommendations that are relevant for both children and adolescents/adults with PAH-CHD, 26 and (2) PPHN and BPD/chronic lung disease in infancy. 27 ▸ Finally, detailed recommendations on therapy are given in two documents: (1) treatment of acute PH in the intensive care unit, including ventricular assist device (VAD)/extracorporeal membrane oxygenation and lung transplantation (LuTx), 28 and (2) comprehensive recommendations on mid- Table 4 Recommendations on the use of genetic testing and biomarkers in children with PH. 22 
Recommendations COR LOE
Genetic counselling is recommended for families with children suffering from severe genetic disorder. This includes children with IPAH or HPAH. I B
Families of patients with syndromes associated with PAH should be educated on the symptoms of PAH and recommended to seek clinical evaluation if the child should develop symptoms of PAH.
I C
It is recommended to screen asymptomatic PAH mutation carriers, also children, with serial echocardiograms, and potentially other non-invasive studies I C Genetic testing for PAH-associated genes such as ACVRL1, BMPR2, CAV1, ENG and KCNK3 can be useful for children with PAH of unknown cause to allow definition of aetiology, estimation of prognosis and identification of family members at risk, and to inform family planning.
IIa C
Genetic testing of first-degree relatives of an index patient with PAH and a known disease-causing mutation can be useful for risk stratification and rationalising surveillance.
Genetic testing for mutations in EIF2AK4 gene should be considered for children with suspicion of PVOD to allow for definition of aetiology and identification of family members at risk, and to inform family planning.
IIa C HPAH patient's family members who develop new cardio-respiratory symptoms should be evaluated immediately for PAH I C
Comprehensive NGS panels targeting all known genetics in PAH can be considered to maximise diagnostic efficacy and increase cost-effectiveness in genetic diagnostics IIb C Genetic testing for PAH-associated genes can be considered for patients with CHD and 'out of proportion' PAH (eg, PAH with small atrial shunt). IIb C Measurement of natriuretic peptides BNP or NT-proBNP is recommended to evaluate disease severity, progression and treatment response in patients with PH.
I B
It is uncertain whether analysis of uric acid levels can be used to evaluate disease severity IIb C Analysis of circulating endothelial cells can be useful to stratify operative risk, evaluate for progression of disease and/or response to therapy in children with PAH
IIa B
The above recommendations of the European Paediatric Pulmonary Vascular Disease Network relate to the grading system currently suggested by the European Society of Cardiology and the American Heart Association and are based on paediatric data only (class, LOE). The complete list of references on the above subtopic can be found in ref. 22 . ACVRL1 (ALK1), activin-like kinase-type 1; BMPR2, bone morphogenetic protein receptor 2; BNP, brain natriuretic peptide; CAV1, caveolin 1; CHD, congenital heart disease; COR, class of recommendation; EIF2AK4, eukaryotic translation initiation factor 2-α kinase 4; ENG, endoglin; HPAH, hereditary pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension; KCNK3, potassium channel subfamily K, member 3; LOE, level of evidence; NGS, next-generation sequencing; NT-proBNP, N-terminal fragment of pro-brain natriuretic peptide; PH, pulmonary hypertension; PVOD, pulmonary veno-occlusive disease. 
Recommendations COR LOE
In children with end-stage disease, timely referral to and discussion with a transplant centre should be sought, if lung transplantation represents a considerable option for the individual patient.
I C
For children with PH/PPHVD undergoing surgery or other interventions requiring sedation or general anaesthesia, consultation with cardiac anaesthesia and the PH service, and appropriate postprocedure monitoring is required.
Good communication between teams, awareness of the severity of the disease, timely preparation (including 'standby' of inhaled nitric oxide) and conscious anaesthetic strategies maintaining an adequate systemic vascular resistance and adequate preload, are recommended to reduce morbidity as well as fatal events I C Female adolescents with PH/PPHVD should undergo timely counselling regarding the significant maternal and foetal pregnancy risks and options for secure contraception.
I B
Paediatric patients with PH in the high-risk category should not participate in competitive sports. I C It is recommended that children with mild-to-moderate PH/PPHVD should engage in light-to-moderate aerobic activity, but be allowed to self-limit their activities as required.
I C Children with PH should avoid strenuous and isometric exercise, as well as dehydration. I C It is recommended that children with PH should only fly on commercial aeroplanes in a stable and compensated condition. I C Children with PH should undergo all recommended routine vaccinations to prevent any deteriorations due to avoidable infections. I C RSV (<2 years of age), pneumococcal and influenza vaccinations should be administered in paediatric patients with PH if no contraindications exist. I C
The above recommendations of the European Paediatric Pulmonary Vascular Disease Network relate to the grading system currently suggested by the European Society of Cardiology and the American Heart Association and are based on paediatric data only (class, LOE). The complete list of references on the above subtopic can be found in ref. 21 Recommendations on PH diagnostics and monitoring, specifically in neonatal chronic lung disease and persistent PH of the newborn, 27 and PAH associated with congenital heart disease,, 26 are outlined in separate articles of the PVD network. 6MWT, six-minute walk test; COR, class of recommendation; CPET, cardiopulmonary exercise testing; CTEPH, chronic thromboembolic pulmonary hypertension; CXR, chest X-ray; HR-chest CT, high resolution chest CT; LOE, level of evidence; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; PPHVD, paediatric pulmonary hypertensive vascular disease; PVD, Pulmonary Vascular Disease; RSV, respiratory syncytial virus. Table 5 Recommendations on haemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease 23 
Recommendations COR LOE
Cardiac catheterisation is indicated in all paediatric patients with PH to confirm diagnosis, evaluate the severity and when PH-specific drug therapy is considered.
I C Initial cardiac catheterisation should include right as well as left heart catheterisation to establish the diagnosis (not only RHC), if there is no contraindication.
I C Cardiac catheterisation may be omitted in acutely presenting, critically ill patients requiring immediate initiation of therapy I B
Cardiac catheterisation for the diagnosis of PAH should include AVT, unless there is a reasonable contraindication, such as PH associated with left heart disease (PH Group II) I C AVT to assess prognosis and indication for specific PH therapy: The haemodynamic change that defines a positive response to AVT in PH without shunt (Qp:Qs=1:1) for children should be considered as a >20% fall in mean PAP and PVRi/SVRi ratio without a decrease in cardiac output IIa C Haemodynamic indicators of PH severity are PVRi/SVRi ratio and PVRi, rather than percent fall in mean pulmonary artery pressure during AVT. Severe PH with high PVRi/SVRi ratio and high PVRi requires advanced and/or combination therapy.
IIa C
AVT to assess operability of APAH-CHD: The haemodynamic change that defines a positive response to AVT in PH with shunt (Qp:Qs >1.5:1) for children should be considered as a >20% fall in PVRi and PVRi/SVRi with respective final values<6 iWU and <0.3.
Cardiac catheterisation and acute vasoreactivity testing should be performed in experienced paediatric heart centres, able to manage potential complications such as PH crisis, potentially requiring extracorporeal membrane oxygenation (depending on disease severity).
I C
The patient's level of consciousness during cardiac catheterisation should be consistent in subsequent invasive assessments. I C
The preferred mode to perform cardiac catheterisation in a patient PH/PPHVD who is spontaneously breathing, either awake or moderately sedated. I C Vasoreactivity testing should be performed using nitric oxide as vasodilator. I C Vasoreactivity testing with the initial combination of nitric oxide and oxygen is reasonable and shortens the AVT study. IIa C
The use of calcium channel blocker, intravenous epoprostenol or intravenous adenosine in acute vasoreactivity testing is not recommended in children and may cause harm. AVT, acute vasoreactivity testing; CHD, congenital heart disease; COR, class of recommendation; LOE, level of evidence; PAP, pulmonary artery pressure; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; PPHVD, paediatric pulmonary hypertensive vascular disease; PVRi, indexed pulmonary vascular resistance; RHC, right heart catheterisation; SVRi, indexed systemic vascular resistance. 
Recommendations
COR LOE cMRI without anaesthesia/sedation is recommended in children with suspected PH/PPHVD as part of the diagnostic evaluation and during follow-up to assess changes in ventricular function and chamber dimensions.
I B
It is recommended that a cMRI study of a child with suspected PH/PPHVD should include the following modules. Cine cMRI for the assessment biventricular volume, function and mass using a stack of axial or short axis slices covering the entire heart.
A cMRI study of a child with suspected PH/PPHVD should include the following modules: Standard 2D flow (PCMRI) measurements at the MPA, RPA, LPA, AAO. I B
A cMRI study of a child with suspected PH/PPHVD may include the following modules: standard 2D flow (PCMRI) measurements at the pulmonary veins. IIb B
A cMRI study of a child with suspected PH/PPHVD may include the following modules: late gadolinium enhancement may be considered for the assessment of presence and amount of myocardial fibrosis.
IIb C
It is uncertain whether a cMRI study of a child with suspected PH/PPHVD should include simultaneous invasive pressure measurements (cMRI guided cardiac catheterisation) to calculate PVR (combined with pulmonary flow measurements) and/or to assess load-independent indices of ventricular function (combined with ventricular flow measurements).
A cMRI study of a child with suspected PH/PPHVD may include the following modules: gadolinium contrast-enhanced or non-contrast-enhanced angiography to assess morphology and size of the pulmonary arteries, pulmonary arterial tree and quantify pulmonary perfusion (CE-MRI).
It is uncertain whether a cMRI study of a child with suspected PH/PPHVD should include the following modules: Assessment of regional RV myocardial function by cMRI tagging techniques.
It is uncertain whether a CMR study of a child with suspected PH/PPHVD should include the following modules: Non-invasive estimation of RV afterload variables, including RVP/PAP/PVR using different proposed cMRI techniques (interventricular septal position, flow measurements, pulmonary distensibility and elastance, RV-PA coupling).
IIb C High-resolution chest CT with angiography is recommended in the initial assessment of a child with suspected PH/PPHVD. I C
In case an obvious cause for PH/PPHVD, such as left-to-right cardiovascular shunt, a chest CT may be omitted. IIb C High-resolution chest CT is indicated in every patient being evaluated for lung transplantation. I C
The above recommendations of the European Paediatric Pulmonary Vascular Disease Network relate to the grading system currently suggested by the European Society of Cardiology and the American Heart Association, and were based on paediatric data only (class, LOE). The complete list of references on the above subtopic can be found in ref. 25 . 2D, two-dimensional; AAO, ascending aorta; cMRI, cardiovascular MRI; CE-MRI, contrast-enhanced MRI; COR, class of recommendation; LOE, level of evidence; LPA, left pulmonary artery; MPA, main pulmonary artery; PAP, pulmonary artery pressure; PH, pulmonary hypertension; PCMRI, phase-contrast MRI; PPHVD, paediatric pulmonary hypertensive vascular disease; PVR, pulmonary vascular resistance; RPA, right pulmonary artery; RVP, right ventricular pressure; RV-PA, right ventricular-pulmonary arterial.
Table 8 Recommendations on the evaluation and management of PH in children and adolescents with CHD (CHD-PAH, CHD-PPHVD) 26
Recommendations COR LOE Children/adolescents with clinically confirmed CHD should undergo specific transthoracic echocardiography (TTE) screening for PAH and/or ventricular dysfunction. TTE cannot reliably distinguish between PAH with increased PVR (PPHVD) and without elevated PVR.
I C
In children and adolescents with PAH/PPHVD-CHD, a complete diagnostic work-up needs to be performed in order to determine whether PAH is associated or causally related to concomitant CHD.
Operability/catheter intervention: Surgery or interventional closure for CHD with simple post-tricuspid shunts (VSD, PDA) and significant left-to-right shunting should preferably be performed within the first 6 months of life.
Children with PAH-CHD and significant left-to-right shunting, congestive heart failure (pulmonary congestion), failure to thrive, and SpO2 >95% (lower extremities) can be considered "operable" for shunt closure; however, perioperative PH crisis may occur.
IIa C
Children with PAH-CHD, significant left-to-right shunting and uncertainties regarding the PVR are recommended to undergo comprehensive right and left heart catheterisation regardless of the patient's age. In children/adolescents with single ventricle physiology, the haemodynamic threshold for operability pre Fontan surgery is probably a mean TPG <6 mm Hg IIa C
In clinically asymptomatic children/adolescents with single ventricle physiology and total cavopulmonary connection (Fontan), a PVRI <3 WU×m 2 and mean TPG <6 mm Hg is consistent with acceptable haemodynamics.
Children/adolescents with total cavopulmonary connection (Fontan) signs of increased PVRI and/or low Qp and/or hepatic congestion should undergo complete diagnostic work-up, including comprehensive cardiac catheterisation.
In children/adolescents with total cavopulmonary connection (Fontan) and PHVD (TPG is ≥6 mm Hg), or those Fontan patients with symptoms irrespective of haemodynamics, targeted PH therapies should be considered to improve exercise capacity.
In inoperable children/adolescents with Eisenmenger syndrome, targeted pharmacotherapy as single drug or combination therapy (sequential, upfront) may be used, depending on WHO functional class and symptoms.
In inoperable children/adolescents with Eisenmenger syndrome, iron supplementation (by mouth, intravenously) may be administered if iron deficiency is present. IIb C
In inoperable children/adolescents with Eisenmenger syndrome, supplemental oxygen may be considered to reduce symptoms after careful examination (when PaO 2 <60 mm Hg). IIb C
In inoperable children with Eisenmenger syndrome and neurological symptoms (headaches, TIA, stroke), phlebotomy may be indicated in severe hyperviscosity syndrome (MCV >80 fL).
IIb C
In inoperable children/adolescents with Eisenmenger syndrome, anticoagulation may be considered in the absence of haemoptysis. IIb C
In children/adolescents with PAH/PPHVD-CHD and left heart congestion either due to obstruction or secondary to myocardial dysfunction, it is recommended to perform full haemodynamic evaluation by comprehensive right and left heart catheterisation.
I C
The above recommendations of the European Paediatric Pulmonary Vascular Disease Network relate to the grading system currently suggested by the European Society of Cardiology and the American Heart Association and are based on paediatric data only (class, LOE 30 
Class of recommendation (COR), level of evidence (LOE)
The recommendations relate to the grading system for class of recommendation (COR) and LOE currently proposed by the ESC and the AHA (COR, table 1; LOE, table 2 ) and was based on paediatric data only ( paediatric studies, or adult studies enrolling >10% children). The grading and voting process is described further below. Within this executive summary, only the recommendations listed in each table #1 of the 9 subtopic consensus statements are listed. A full list of references can be found in the individual 9 subtopic articles. In infants with severe BPD with or without PH, treatment with diuretics, that is, hydrochlorothiazide and spironolactone, can be considered as long as cardiac preload is adequate.
IIa B
All infants with proven or suspected PH should receive close follow-up, including preductal/postductal SpO2 measurements, echocardiography (1/week initially, then 1-2/month), and laboratory work-up depending on disease severity including NT-proBNP, BNP, troponin optional, guided by clinical improvement or lack thereof.
I C
The above recommendations of the European Paediatric Pulmonary Vascular Disease Network relate to the grading system currently suggested by the European Society of Cardiology and the American Heart Association and are based on paediatric data only (class, LOE). The complete list of references on the above subtopic can be found in ref. 27 . BPD, bronchopulmonary dysplasia; CLD, chronic lung disease; COR, class of recommendation; ECMO, extracorporeal membrane oxygenation; LOE, level of evidence; iNO, inhaled nitric oxide; NT-proBNP, N-terminal fragment of pro-brain natriuretic peptide; PGE, prostaglandin E; PPHN, persistent pulmonary hypertension of the newborn; PH, pulmonary hypertension; VSD, ventricular septal defect.
Table 10
Recommendations on the therapy of acute PH in the paediatric intensive care unit 28 Recommendations COR LOE Oxygen should be given when transcutaneous oxygen saturation is <95% in children with PH and normal cardiac anatomy.
I C Intravenous prostanoids should be considered to treat children with severe PH. IIa B iNO may be considered for treatment of postoperative PH in mechanically ventilated patients to improve oxygenation and reduce the risk of pulmonary hypertensive crisis.
IIb B
Concomitant sildenafil should be administered to prevent rebound PH in patients who have signs of increased PAP on withdrawal of iNO, and require restart of iNO despite preceding gradual weaning of iNO.
I B
Intravenous sildenafil may be considered for treatment of PH in critically ill patients, especially those with an unsatisfactory response to iNO. IIb B
Inhaled iloprost may be as effective as iNO in children with postoperative PH. IIb B
In children who develop signs of low cardiac output or profound pulmonary failure despite optimal medical therapy, extracorporeal life support may be considered.
IIb C
The above recommendations of the European Paediatric Pulmonary Vascular Disease Network relate to the grading system currently suggested by the European Society of Cardiology and the American Heart Association and are based on paediatric data only (class, LOE). The complete list of references on the above subtopic can be found in ref. 28 . COR, class of recommendation; ICU, intensive care unit; iNO, inhaled nitric oxide; LOE, level of evidence; PAP, pulmonary artery pressure; PH, pulmonary hypertension. Importantly, healthcare providers must adhere to the medication labelling and follow future drug recommendations/warnings potentially published by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) when transforming these recommendations into clinical practice.
Voting process
The WG held five face-to-face meetings to discuss the individual topics and conduct the voting on the wording of the recommendations and the grading (COR, LOE) thereof (tables 1 and 2). The according meetings were conducted on 28 January 2014 in Bad Nauheim, Germany; on 28 July 2014 in Hannover, Table 11 Recommendations on treatment of children with paediatric pulmonary hypertension 29 
Recommendations COR LOE
Oxygen therapy is reasonable in hypoxemic PH patients who consistently have oxygen saturations <92% or PaO 2 <60 mm Hg IIa C Inhalative oxygen can be particularly useful for patients with pulmonary hypertension and an element of parenchymal lung disease (eg, bronchopulmonary dysplasia/nCLD).
IIa B
Inhalative oxygen can be useful for patients with intrapulmonary shunt and important for patients with PH while at altitude or during air travel. IIa C Based on PAH and heart failure studies in adults, mineralcorticoid receptor blockade with spironolactone can be beneficial in patients with PAH by improving RV and LV diastolic function, particularly in 'heart failure with preserved ejection fraction'.
IIa C
Diuretic therapy may be considered for selected paediatric patients with pulmonary hypertension. IIb C Diuretic therapy should be initiated cautiously since patients with PH/PPHVD are often pre-load dependent to maintain an optimal cardiac output. I C
The benefit of chronic anticoagulation (warfarin, phenprocoumon) in children with PAH is unclear (so far not studied in children). IIb C Chronic anticoagulation can be useful in patients with progressive IPAH/HPAH (empirical goal INR 2.0-2.5), patients with chronic thromboembolic pulmonary hypertension, patients with low cardiac output and those with hypercoagulable states.
IIa C Indication for anticoagulation should be critically reviewed, especially in small children prone to haemorrhagic complications. In these cases, antiplatelet therapy (eg, ASA) may be an alternative.
IIb C Anticoagulation is potentially harmful in children with hereditary haemorrhagic telangiectasia or porto-pulmonary hypertension. III harm C Before starting targeted PAH therapy for chronic PH/PPHVD, vasodilator responsiveness should be determined by cardiac catheterisation and anatomic obstruction from pulmonary venous disease or from left-sided heart disease should be excluded.
I B
CCB: A trial of CCB monotherapy should be pursued only in those patients who have previously been shown to be acutely reactive to iNO±oxygen, that is, those who have a positive acute vasoreactivity response ('AVT responders').
IIa C For children with a negative acute vasoreactivity response or those with a failed or non-sustained response to CCBs, risk stratification should probably determine additional targeted therapy.
IIa C CCB are contraindicated in children who have not undergone AVT, non-responders to AVT, and those with right heart failure, that is, WHO functional class IV, regardless of acute vasodilatory response (due to potential negative inotropic effect of CCB, especially in patients with low cardiac output).
III harm C
The majority of children with severe PAH are non-responsive to acute vasodilator testing to iNO±oxygen, and require 'targeted' therapy other than CCB.
I C
In a child with mild-to-moderate chronic PH/PPHVD and lower risk (figure 1), initiation of oral goal-targeted therapy is recommended (figures 2 and 3), regardless of a negative acute vasoreactivity response and should begin with either a PDE5-inhibitor or an endothelin receptor antagonist.
I B
Oral sildenafil can be useful in the setting of iNO therapy withdrawal in post-operative PH, or in the presence of PH related to chronic lung disease. IIa B
High-dose oral sildenafil treatment (defined in the STARTS-1/-2 RCT, and table 2), either as monotherapy or add-on drug, carries an unfavourable risk-to-benefit ratio in children (>8 kg, >1-year-old) with PAH/PPHVD, including potentially increased mortality. IIb C iNO is mainly used in the intensive care unit setting and useful in patients with acute pulmonary vascular crisis and/or acute exacerbation of PH in the setting of an underlying parenchymal lung disease and/or PPHN.
Atrial septostomy can be considered in patients in functional class III and IV and recurrent syncope under combined medical therapy, and as palliative bridge to transplant increasing the chance for survival while waiting for a donor organ.
IIb C Based on a small series of children with end-stage PAH, a surgical anastomosis between the left pulmonary artery and the descending aorta (Potts shunt) may be considered be a valuable alternative (destination therapy) or bridge to bilateral lung transplantation in selected cases.
IIb C
The recommendations of the European Paediatric Pulmonary Vascular Disease Network relate to the grading system currently suggested by the European Society of Cardiology and the American Heart Association and are based on paediatric data only (class, level of evidence). The complete list of references on the above subtopic can be found in ref. 29 .
Recommendations on PH therapy, specifically in neonatal chronic lung disease and PPHN, 27 and PAH associated with congenital heart disease, 26 and the recommendations on acute PH in the intensive care unit, 28 are outlined in the according subtopic articles of this expert consensus statement. AVT, acute vasodilator testing; CCB, calcium channel blocker; COR, class of recommendation; HPAH, hereditary pulmonary hypertension; iNO, inhaled nitric oxide; IPAH, idiopathic pulmonary arterial hypertension; LOE, level of evidence; LPA, left pulmonary artery; LV, left ventricle; PAH, pulmonary arterial hypertension; PAP, pulmonary artery pressure; PH, pulmonary hypertension; PPHN, persistent pulmonary hypertension of the newborn; PPHVD, paediatric pulmonary hypertensive vascular disease; RCT, randomised controlled trial; RV, right ventricle. and 7 determined as class III (COR III, no benefit or harm). Three recommendations were LOE A, 41 were LOE B and the majority, that is, 100, were stratified as LOE C, due to the lack of randomized controlled studies. Figure 1 Diagnostic algorithm for a child or adolescent with suspected pulmonary hypertension. BPD, bronchopulmonary dysplasia; CLD, chronic lung disease; CHD, congenital heart disease; CTEPH, chronic thromboembolic pulmonary hypertension; CXR, chest X-ray; HPAH, hereditary pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension; PCH, pulmonary capillary haemangiomatosis; PH, pulmonary hypertension; PVOD, pulmonary veno-occlusive disease; VQ, ventricular-perfusion. Figure 2 Determinants of risk in paediatric pulmonary hypertensive vascular disease. The variables listed distinguish between lower and higher risk. The intermediate risk group is broad and not specifically defined. Overall, these determinants have only level of evidence C due to sparse or lack of paediatric data. Healthcare providers may include here PVR/SVR ratio, the 6 min walk distance and the max. oxygen consumption (VO 2 max.) obtained during cardiopulmonary exercise testing as risk variables; however, it is unclear where exactly the cut-off values should be set. One must also note that most of these variables have been validated mostly for IPAH and the cut-off levels used above may not necessarily apply to other forms of PAH. Furthermore, the use of approved therapies and their influence on the variables should be considered in the evaluation of the risk. BNP, brain natriuretic peptide; CI, cardiac index (syn. Qs); IPAH, idiopathic pulmonary arterial hypertension; mPAP, mean pulmonary artery pressure, mRAP, mean right atrial pressure; NT-proBNP, N terminal pro BNP; PVRi, pulmonary vascular resistance index; RA, right atrium; RV, right ventricle; SVRi, systemic vascular resistance index; WHO, World Health Organisation. Modified from McLaughlin and McGoon. Figure 3 Algorithm for management of patients with congenital heart disease associated with PAH/PPVD and congenital shunt lesions. The indication for invasive diagnostics and eligibility for surgery/operability by comprehensive right and left heart catheterisation includes basic evaluation and AVT, the latter especially in the grey zone of forecast uncertainty. Modified from: Lopes AA and Barst R and the PVRI PAH-CHD taskforce (PVRI website; published on 26 September 2013). ASD, atrial septal defect; AVT, acute vasodilative testing; CHD, congenital heart disease; PDA, patent ductus arteriosus; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; pre OP, preoperatively; PVR, pulmonary vascular resistance; PVRI, pulmonary vascular resistance index; Qp, pulmonary blood flow; Qs, systemic blood flow; SVR, systemic vascular resistance; WU, Wood units; VSD, ventricular septal defect PAH, pulmonary arterial hypertension. Figure 4 Treatment algorithm for paediatric pulmonary arterial hypertension. This algorithm applies to IPAH HPAH (FPAH). Solid clinical data on the therapy of other forms of PH is limited. The 'intermediate' risk group is broad and not specifically defined (see figure 1) . Healthcare providers may consider upfront, early or rapid sequence-targeted PAH therapy in 'intermediate' risk group (between 'lower risk' and 'higher risk' in figure 1: 'Determinants of risk'). Use of all agents is considered off-label in children aside from sildenafil and bosentan (>1-year-old) in Europe. Sildenafil dosing recommendations should follow EMA-approved dosing for children. Bosentan received the following dual grading: COR I, LOE B for children with PAH and Eisenmenger syndrome, and COR IIa, LOE C for children with PAH without Eisenmenger syndrome. CCB, calcium channel blocker; COR, class of recommendation; ERA, endothelin receptor antagonist; EMA, European Medicines Agency; HPAH, hereditary pulmonary arterial hypertension; inh., inhalation; IPAH, idiopathic pulmonary arterial hypertension; IV, intravenous; LOE, level of evidence; PDE-5i, phosphodiesterase 5 inhibitor; PH, pulmonary hypertension;; PAH, pulmonary arterial hypertension; SC, subcutaneous. Modified and expanded from Ivy et al.
Peer review process
Each manuscript of the multipaper expert consensus statement has been peer reviewed by at least two anonymous external experts according the journal's standardised review process for original articles and-in addition-by two anonymous experts selected by the International Society of Heart and Lung Transplantation (ISHLT) scientific board.
Endorsement process (ISHLT, DGPK)
The ISHLT was actively involved in the peer review process as outlined above and endorsed the first five manuscripts on 3 September 2015 and the final five manuscripts on February 9, 2016. The DGPK, that is, the society for paediatric and congenital cardiology in Austria, Germany and Switzerland, endorsed the multipaper expert consensus statement on January 7, 2015 (box 2).
Summary of graded recommendations (COR, LOE) by clinical topic
See tables 3-11 and figures 1-5 for summary of graded recommendations.
Limitations of the multipaper expert consensus statement on paediatric PH
We acknowledge that most LOE of our recommendations on paediatric PH, are B or C, since only very few randomised controlled trials have been conducted so far due the heterogeneity of what is still considered a rare-but underdiagnosed-disease in the so-called developed world. Thus, we called this special issue 'Expert Consensus Statement' rather than 'Guidelines'. We Figure 5 Treatment algorithm for combination therapy in PAH (evidenced-based only for adults with PAH, ie, group 1 PH). Bosentan received the following dual grading: COR I, LOE B for children with PAH and Eisenmenger syndrome, and COR IIa, LOE C for children with PAH without Eisenmenger syndrome. The 'intermediate' risk group is broad and not specifically defined (see figure 1) . (a) Some WHO-FC III patients may be considered high risk (see table 1 ). (b) In adult PAH, initial combination with ambrisentan plus tadalafil has been shown to be superior to initial monotherapy with ambrisentan or tadalafil in delaying clinical failure. (c) Intravenous epoprostenol should be prioritised as it has reduced the 3 months rate for mortality in high-risk adult PAH patients also as monotherapy. (d) Consider also balloon atrial septostomy. Modified from Galie et al. 30 CCB, calcium channel blockers; COR, class of recommendation; DPAH, drug-induced PAH; HPAH, heritable PAH; IPAH, idiopathic PAH; i.v., intravenous; LOE, level of evidence (according to European Society of Cardiology and American Heart Association). PAH, pulmonary arterial hypertension; PCA, prostacyclin analogues; WHO-FC, WHO functional class.
Box 3 Challenges and future directions of the European Paediatric Pulmonary Vascular Disease Network
▸ Identification of valid treatment goals in paediatric PAH. 6 32-35 ▸ Regulatory requirements, patient recruitment and retention, clinical trial endpoints for paediatric PAH trials. 33 34 ▸ Need to conduct multicentre studies and establish new registries for paediatric pulmonary hypertension. 14 34 ▸ Initiation of a prospective multicentre study on early combination therapy in paediatric including a comparative group (early combined dual or triple combination, rapid sequence of two agents). ▸ When and how to perform a Potts shunt procedure 36 (surgery, intervention?) for advanced PAH and how to combine this pressure-unloading shunt with combination pharmacotherapy? ▸ Initiation of investigator-initiated pilot and/or industry-sponsored phase 2/3 studies on the safety and efficacy of new compounds recently published/approved for adult PAH (macitentan, riociguat, selexipag, treprostinil).
Key messages
What is already known on this subject? Pulmonary hypertension (PH) in neonates, infants, children and adolescents is a complex condition that may be associated with diverse cardiac, pulmonary and systemic diseases, and contributes to significant morbidity and mortality. However, current approaches to caring for paediatric patients with PH have been limited by the lack of consensus recommendations from experts in the field of paediatric PH.
What might this study add?
The European Paediatric Pulmonary Vascular Disease (PVD) Network is a registered, non-profit organisation that strives to define and develop effective, innovative diagnostic tools and treatment options in all forms of paediatric pulmonary hypertensive vascular disease (PHVD), including specific forms such as pulmonary arterial hypertension-congenital heart disease, PH associated with bronchopulmonary dysplasia, persistent PH of the newborn, and related cardiac dysfunction. In order to achieve these objectives, a multipaper expert consensus statement was developed to provide comprehensive and practical recommendations.
How might this impact on clinical practice?
This multipaper expert consensus statement of the European Paediatric PVD Network provides-for the first time-a specific, comprehensive, detailed but practical framework for the optimal clinical care of children with PH/PHVD.
